News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,694 Results
Type
Article (14901)
Company Profile (299)
Press Release (266488)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79864)
Career Advice (162)
Deals (13342)
Drug Delivery (39)
Drug Development (50700)
Employer Resources (31)
FDA (5838)
Job Trends (5168)
News (145113)
Policy (10076)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21766)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6032)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43668)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (551)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31644)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51680)
Executive appointments (621)
FDA (7585)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (981)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6613)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2665)
Medtech (2674)
Mergers & acquisitions (6619)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2039)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26666)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20286)
Phase 3 (12823)
Pipeline (3240)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1449)
Recruiting (12)
Regulatory (9893)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (124)
Series A (182)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1205)
Last 365 days (17798)
2026 (1651)
2025 (18101)
2024 (20547)
2023 (22416)
2022 (26825)
2021 (27808)
2020 (23362)
2019 (16230)
2018 (11741)
2017 (13749)
2016 (11846)
2015 (14360)
2014 (10415)
2013 (7498)
2012 (7538)
2011 (7622)
2010 (7431)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18254)
Australia (3110)
California (7075)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39163)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5579)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1761)
North Carolina (826)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (904)
United States (23324)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,694 Results for "heron therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
August 11, 2025
·
11 min read
Press Releases
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
August 11, 2025
·
16 min read
Press Releases
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
August 18, 2025
·
3 min read
Press Releases
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
July 29, 2025
·
2 min read
Press Releases
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
August 8, 2025
·
2 min read
Press Releases
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
April 28, 2025
·
4 min read
Press Releases
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
May 6, 2025
·
2 min read
Press Releases
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
May 7, 2025
·
14 min read
Press Releases
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
April 23, 2025
·
2 min read
Business
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.
May 7, 2024
·
15 min read
1 of 28,170
Next
